HC Wainwright Has Weak Estimate for Talphera FY2029 Earnings

Talphera, Inc. (NASDAQ:TLPH) – Equities research analysts at HC Wainwright dropped their FY2029 earnings per share (EPS) estimates for shares of Talphera in a research report issued on Thursday, August 13th. HC Wainwright analyst B. Folkes now expects that the company will earn $0.12 per share for the year, down from their prior estimate of $0.13. HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for Talphera’s current full-year earnings is ($0.26) per share. HC Wainwright also issued estimates for Talphera’s FY2030 earnings at $0.32 EPS.

Other equities research analysts have also issued research reports about the stock. Zacks Research upgraded shares of Talphera to a “hold” rating in a report on Monday, June 8th. Westpark Capital started coverage on Talphera in a research report on Thursday, April 30th. They set a “buy” rating and a $3.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Talphera in a report on Friday, July 17th. Finally, Wall Street Zen upgraded Talphera to a “hold” rating in a research note on Saturday, August 8th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Talphera has a consensus rating of “Hold” and an average target price of $3.00.

Talphera Price Performance

NASDAQ:TLPH opened at $1.21 on Friday. Talphera has a 1-year low of $0.40 and a 1-year high of $1.57. The company has a 50-day moving average of $1.19 and a 200 day moving average of $0.96. The firm has a market cap of $62.80 million, a PE ratio of -4.48 and a beta of 0.69.

Talphera (NASDAQ:TLPH) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.06) EPS for the quarter, meeting the consensus estimate of ($0.06).

Hedge Funds Weigh In On Talphera

Institutional investors have recently modified their holdings of the stock. Cantor Fitzgerald L. P. acquired a new position in shares of Talphera in the 4th quarter valued at about $658,000. Diadema Partners LP acquired a new stake in Talphera during the fourth quarter worth about $156,000. Persistent Asset Partners Ltd acquired a new stake in Talphera during the fourth quarter worth about $42,000. Mariner LLC raised its position in Talphera by 132.0% during the fourth quarter. Mariner LLC now owns 58,000 shares of the company’s stock valued at $66,000 after acquiring an additional 33,000 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in Talphera by 412.6% in the fourth quarter. Renaissance Technologies LLC now owns 257,380 shares of the company’s stock valued at $293,000 after acquiring an additional 207,166 shares during the period. Hedge funds and other institutional investors own 37.67% of the company’s stock.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.